You are here : Home > Research Entities > Medicines and healthcare techn ... > Pharmacology and Immunoanalysis unit

SPI

Pharmacology and Immunoanalysis unit

Published on 15 February 2019
For 30 years, the Pharmacology and Immunoanalysis (SPI) unit has been demonstrating its expertise in the development of immunoanalytical methods, physicochemical analyzes (especially LC-MS) and cell culture enabling it to address multiple issues concerning detection, quantification and future development of molecules of various and varied kinds.

 

Head of Unit
Christophe Junot
01 69 08  43 66
christophe.junot@cea.fr

Deputy
Stéphanie Simon
33 1 69 08 77 04
stephanie.simon@cea.fr

Secretary

Laurie MENEZ
01 69 08 51 39

Sandrine LEBLOIS
01 69 08 72 99

Stéphanie NANO
01 69 08 45 83

The research carried out in SPI always connects with the fundamental aspects of the methodological and analytical developments and always integrates the "Therapeutic Innovation and Diagnostic" line of the CEA's Fundamental Research Division. Research is usually carried out in collaboration with academic partners or contract with industry or government partners.

The themes developed by the Drug Metabolism Research Laboratory  (LEMM) rely on a large fleet of mass spectrometers and revolve around:
  • the development of new methods of detection, identification and quantification of drugs and their metabolites, as well as recombinant proteins or pathogens,
  • the development of metabolomic, lipidomic and glycomic approaches in the search for diagnostic biomarkers or pathologies monitoring,
  • the development of cell models (in particular an in vitro model of blood brain barrier) for neurovascular pharmacology
  • the engineering of antibodies for therapy and diagnostic by imaging
The subjects of the Immunoanalysis Studies and Research Laboratory (LERI) all involve the "antibody molecule" through the means of production of polyclonal and monoclonal antibodies at its disposal to develop:
  • diagnostic methods (ELISA and immuno-chromatographic tests) for various types of targets: xenobiotics, proteins and especially pathogens handled in the laboratory L3 available at LERI,
  • new technological developments around the "fast" dosages like immunochromatography, 
  • immunotherapeutic or vaccine approaches

The mission of the Technological Innovations for Detection and Diagnosis Laboratory (LI2D), based on the CEA site of Marcoule, is to develop methodologies and technologies for the detection of pathogens or toxic substances found in the environment or in biological samples / tissues and the discovery and validation of biomarkers for diagnosis. 
The research carried out at Li2D is based on his expert knowledge in microbiological, immunological, genetic, genomic, proteomic, bioinformatics and high-resolution mass spectrometry techniques. 

The work done at the Food Immuno-Allergy Unit (UIAA) aims to develop tools and knowledge to assess, manage and if possible prevent food-related allergic risk.

Indeed, food allergies are a major public health problem because of the increase in prevalence, but also the number of affected food and the severity of clinical symptoms they cause. Therefore, it is a challenge and a concern for the Food Industry and the Public Authorities in charge of the health of consumers to have means to assess, manage and if possible prevent the allergic risks of food.

Finally, since its inception, the SPI has developed commercialization projects that proved particularly successful (Prion or bioterrorism agents dosage, for example), by the realization of numerous contractual studies or collaborative research with industrial partners in pharmaceuticals and diagnostics for over twenty years ("spin-off" from our developments).The existence of a strong quality policy also contributes to the identity of our service: the presence of two full-time quality professionals, accreditation of Good Laboratory Practices (ANSM) of LEMM and iso9001 certification of SPI obtained on December 2014 (LI2D in 2003).

 Publications

2019
before 2019